Key result
Stakeholders anticipated initial hesitancy toward nOPV2 due to safety concerns, but felt the vaccine would ultimately be accepted with strategic communication.
Why the study?
Although nOPV2 was introduced to address cVDPV2, it may lack immediate community and health worker trust due to novelty, potential side effects, and Emergency Use Listing introduction.
Strategic communication interventions addressing key concerns are needed to improve community acceptance of the novel oral polio vaccine Type 2.
No takes yet. Share an insight, caveat, or question.
May warrant proactive communication strategies for nOPV2 rollout; leaves open prospective validation of acceptance in endemic settings.
Lorenzetti et al. (2022) studied circulating vaccine-derived poliovirus Type 2 (cVDPV2). novel oral polio vaccine Type 2 (nOPV2) was evaluated on Awareness, attitudes/beliefs, and concerns about cVDPV2 and nOPV2. Stakeholders anticipated initial hesitancy toward nOPV2 due to safety concerns, but felt the vaccine would ultimately be accepted with strategic communication.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: